IGMS

1.32

2.33% 0.03

Handel nachbörslich: 1.35 0.03 +2.27%

Igm Biosciences Inc (IGMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.29

Offen:

$1.31

24-Stunden-Volumen:

2.34M

Relative Volume:

13.54

Marktkapitalisierung:

$81.16M

Einnahmen:

$2.91M

Nettoeinkommen (Verlust:

$-220.40M

KGV:

-0.3626

EPS:

-3.64

Netto-Cashflow:

$-176.15M

1W Leistung:

+9.09%

1M Leistung:

+4.76%

6M Leistung:

-78.74%

1J Leistung:

-79.38%

1-Tages-Spanne:

$1.30

$1.35

1-Wochen-Bereich:

$1.08

$1.39

52-Wochen-Spanne:

$0.92

$22.50

Igm Biosciences Inc Stock (IGMS) Company Profile

Firmenname

Igm Biosciences Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

650-965-7873

Adresse

325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-03-31

Neueste SEC-Einreichungen

IGMS's Discussions on Twitter

Vergleichen Sie IGMS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IGMS Igm Biosciences Inc	1.32	81.16M	2.91M	-220.40M	-176.15M	-3.64
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-10	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2025-01-10	Herabstufung	Guggenheim	Buy → Neutral
2025-01-10	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2025-01-10	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-01-10	Herabstufung	Stifel	Buy → Hold
2024-12-06	Eingeleitet	BMO Capital Markets	Outperform
2024-10-01	Herabstufung	JP Morgan	Neutral → Underweight
2024-10-01	Herabstufung	Truist	Buy → Hold
2024-02-09	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-12-15	Herabstufung	BofA Securities	Buy → Neutral
2023-12-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-11-09	Fortgesetzt	Jefferies	Buy
2022-10-17	Eingeleitet	JP Morgan	Neutral
2022-08-29	Eingeleitet	BofA Securities	Buy
2021-12-13	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-11-05	Hochstufung	Wedbush	Neutral → Outperform
2021-08-26	Eingeleitet	Morgan Stanley	Overweight
2021-01-29	Eingeleitet	RBC Capital Mkts	Outperform
2021-01-19	Bestätigt	H.C. Wainwright	Buy
2020-12-22	Herabstufung	Wedbush	Outperform → Neutral
2020-07-17	Eingeleitet	Robert W. Baird	Outperform
2020-07-01	Eingeleitet	H.C. Wainwright	Buy
2020-05-28	Eingeleitet	SunTrust	Buy
2020-04-22	Eingeleitet	Wedbush	Outperform
2019-10-14	Eingeleitet	Guggenheim	Buy
2019-10-14	Eingeleitet	Jefferies	Buy
2019-10-14	Eingeleitet	Piper Jaffray	Overweight
2019-10-14	Eingeleitet	Stifel	Buy

Alle ansehen

Igm Biosciences Inc Aktie (IGMS) Neueste Nachrichten

Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025

Jun 12, 2025

IGM Biosciences price target lowered to $1 from $2 at Truist - Yahoo Finance

Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025

Jun 11, 2025

IGM Biosciences Faces Nasdaq Non-Compliance Notice - TipRanks

Jun 11, 2025

Truist Revises IGM Biosciences (IGMS) Price Target to $1 | IGMS Stock News - GuruFocus

Jun 11, 2025

Truist Cuts Price Target on IGM Biosciences to $1 From $2, Keeps Hold Rating - MarketScreener

Jun 11, 2025

IGM Biosciences (NASDAQ:IGMS) Cut to "Sell" at Wall Street Zen - MarketBeat

Jun 11, 2025

Jun 09, 2025

Millennium Management LLC Sells 69,074 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World

Jun 09, 2025

Jun 08, 2025

Two Sigma Investments LP Grows Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World

Jun 08, 2025

Jun 07, 2025

IGM Biosciences (NASDAQ:IGMS) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 07, 2025

Jun 05, 2025

IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat

Jun 05, 2025

Jun 03, 2025

IGM Biosciences (NASDAQ:IGMS) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Jun 03, 2025

Jun 02, 2025

IGM Biosciences Reports Increased Net Loss Amid Strategic Focus - TipRanks

Jun 02, 2025

Jun 01, 2025

Wall Street Zen Upgrades IGM Biosciences (NASDAQ:IGMS) to “Hold” - Defense World

Jun 01, 2025

May 31, 2025

IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Reduce” from Analysts - Defense World

May 31, 2025

May 29, 2025

IGM Biosciences Terminates Headquarters Lease Agreement - TipRanks

May 29, 2025

IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025

May 22, 2025

IGM Biosciences earnings missed by $0.51, revenue fell short of estimates - Investing.com Canada

May 22, 2025

Sanofi Invests $8.79 Million in IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat

May 22, 2025

May 21, 2025

Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail

May 21, 2025

May 20, 2025

IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com Nigeria

May 20, 2025

IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com

May 20, 2025

May 19, 2025

30,148 Shares in IGM Biosciences, Inc. (NASDAQ:IGMS) Bought by Cubist Systematic Strategies LLC - Defense World

May 19, 2025

May 14, 2025

IGM Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025